Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth H Hammond

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Archives of Pathology & Laboratory Medicine|April 30, 2005
Addressing the maintenance of certification challenge: the College of American Pathologists responseM Elizabeth H Hammond, Constance M Filling, Ann R Neumann, et al.
Journal of Oncology Practice|November 2, 2010
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerM Elizabeth H Hammond, Daniel F Hayes, Antonio C Wolff, et al.
Archives of Pathology & Laboratory Medicine|June 8, 2010
Recommendations for validating estrogen and progesterone receptor immunohistochemistry assaysPatrick L Fitzgibbons, Douglas A Murphy, M Elizabeth H Hammond, et al.
Archives of Pathology & Laboratory Medicine|April 7, 2010
Variable specimen handling affects hormone receptor test results in women with breast cancer: a large multihospital retrospective studyFlory L Nkoy, M Elizabeth H Hammond, William Rees, et al.
JAMA Oncology|September 15, 2022
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)Aleix Prat, Aditya Bardia, Giuseppe Curigliano, et al.
Molecular Cancer Therapeutics|April 14, 2005
Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein BadKevin A Strait, C Terry Warnick, Clyde D Ford, et al.
Molecular Cancer Therapeutics|December 14, 2002
Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteinsKevin A Strait, Bashar Dabbas, Elizabeth H Hammond, et al.
Diagnostic Pathology|October 18, 2023
Evidence of autoinflammation as a principal mechanism of myocardial injury in SARS-CoV-2 PCR-positive medical examiner casesMargo E Hammond, Erik D Christensen, Michael Belenky, et al.
Archives of Pathology & Laboratory Medicine|October 2, 2009
The role of KRAS mutation testing in the management of patients with metastatic colorectal cancerFederico A Monzon, Shuji Ogino, M Elizabeth H Hammond, et al.
International Journal of Radiation Oncology, Biology, Physics|July 20, 2007
Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivoRadka Stoyanova, Paul Hachem, Harvey Hensley, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Archives of Pathology & Laboratory Medicine|April 30, 2005
Addressing the maintenance of certification challenge: the College of American Pathologists responseM Elizabeth H Hammond, Constance M Filling, Ann R Neumann, et al.
Journal of Oncology Practice|November 2, 2010
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerM Elizabeth H Hammond, Daniel F Hayes, Antonio C Wolff, et al.
Archives of Pathology & Laboratory Medicine|June 8, 2010
Recommendations for validating estrogen and progesterone receptor immunohistochemistry assaysPatrick L Fitzgibbons, Douglas A Murphy, M Elizabeth H Hammond, et al.
Archives of Pathology & Laboratory Medicine|April 7, 2010
Variable specimen handling affects hormone receptor test results in women with breast cancer: a large multihospital retrospective studyFlory L Nkoy, M Elizabeth H Hammond, William Rees, et al.
JAMA Oncology|September 15, 2022
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)Aleix Prat, Aditya Bardia, Giuseppe Curigliano, et al.
Molecular Cancer Therapeutics|April 14, 2005
Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein BadKevin A Strait, C Terry Warnick, Clyde D Ford, et al.
Molecular Cancer Therapeutics|December 14, 2002
Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteinsKevin A Strait, Bashar Dabbas, Elizabeth H Hammond, et al.
Diagnostic Pathology|October 18, 2023
Evidence of autoinflammation as a principal mechanism of myocardial injury in SARS-CoV-2 PCR-positive medical examiner casesMargo E Hammond, Erik D Christensen, Michael Belenky, et al.
Archives of Pathology & Laboratory Medicine|October 2, 2009
The role of KRAS mutation testing in the management of patients with metastatic colorectal cancerFederico A Monzon, Shuji Ogino, M Elizabeth H Hammond, et al.
International Journal of Radiation Oncology, Biology, Physics|July 20, 2007
Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivoRadka Stoyanova, Paul Hachem, Harvey Hensley, et al.
Pageof 8